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Abstract (242 words) 
In addition to dopaminergic and motor deficits, patients with Parkinson’s disease (PD) 
suffer from non-motor symptoms, including early cognitive and social impairment, that do 
not respond well to dopaminergic therapy. Cholinergic deficits may contribute to these 
problems, but cholinesterase inhibitors have limited efficacy. Mice over-expressing α-
synuclein, a protein critically associated with PD, show deficits in cognitive and social 
interaction tests, as well as a decrease in cortical acetylcholine. We have evaluated the 
effects of chronic administration of nicotine in mice over-expressing wild type human α-
synuclein under the Thy1-promoter (Thy1-aSyn mice). Nicotine was administered 
subcutaneously by osmotic minipump for 6 months from 2 to 8 months of age at 0.4 
mg/kg/h and 2.0 mg/kg/h. The higher dose was toxic in the Thy1-aSyn mice, but the low 
dose was well tolerated and both doses ameliorated cognitive impairment in Y-maze 
performance after 5 months of treatment. In a separate cohort of Thy1-aSyn mice, 
nicotine was administered at the lower dose for one month beginning at 5 months of age. 
This treatment partially eliminated the cognitive deficit in novel object recognition and 
social impairment. In contrast, chronic nicotine did not improve motor deficits after 2, 4 or 
6 months of treatment, nor modified α-synuclein aggregation, tyrosine hydroxylase 
immunostaining, synaptic and dendritic markers, or microglial activation in Thy1-aSyn 
mice. These results suggest that cognitive and social impairment in synucleinopathies like 
PD may result from deficits in cholinergic neurotransmission and may benefit from chronic 
administration of nicotinic agonists. 
 
Keywords 
Parkinson’s disease, mouse model, α-synuclein, nicotine, motor deficits, cognitive 
deficits, social impairment  
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Highlights 
 Chronic nicotine treatment for five months reverses cognitive deficits in Y-maze 
spontaneous test in Thy1-aSyn mice. 
 Chronic nicotine treatment for one month improves cognitive defects in novel 
object recognition test and social impairment in Thy1-aSyn mice.  
 Chronic nicotine treatment for six months did not alter early motor deficits nor 
modified α-synuclein pathology, tyrosine hydroxylase immunostaining, or 
microglial activation in Thy1-aSyn mice. 
 Chronic administration of nicotinic acetylcholine receptor (nAChR) agonists may 
improve cognitive and social deficits, the debilitating non-motor aspects of early 
PD. 
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Introduction 
In patients with Parkinson’s disease (PD), neurodegeneration primarily affects 
dopaminergic neurons of the substantia nigra (SN) of the midbrain, leading to dopamine 
loss in the striatum and dysregulation of neuronal circuits in the basal ganglia. This 
dopaminergic deficit is the primary cause of the characteristic motor symptoms of the 
disease, bradykinesia, resting tremor, and rigidity.  However, the symptoms of PD 
extend beyond motor dysfunction and also involve non-motor aspects that include 
cognitive deficits, social impairment, sleep disturbances, and sensory and autonomic 
dysfunction (Anderson et al., 2013; Bassetti, 2011; Chaudhuri et al., 2011; Wolters, 
2009). The mechanisms of these non-motor symptoms of PD are only partially 
understood. Dopamine depletion may play a role in non-motor deficits; but their early 
appearance, often before motor deficits, and their poor response to dopaminergic 
treatments suggest additional mechanisms (Abbott et al., 2007; Postuma et al., 2012; 
Ross et al., 2006).  
 
α-Synuclein has emerged as a potential pathogenic factor in PD based on genetic 
evidence that mutation or gene duplication in the SNCA gene cause familial forms of 
PD, and polymorphisms are strongly associated with sporadic PD (Edwards et al., 2010; 
Kruger et al., 1998; Polymeropoulos et al., 1997; Singleton et al., 2003). Furthermore, α-
synuclein is a component of Lewy bodies, a hallmark of PD, and forms aggregates that 
are broadly distributed in the central and peripheral nervous system (Bloch et al., 2006; 
Braak et al., 2006; Spillantini and Goedert, 2000; Spillantini et al., 1997). The 
hypothesis that α-synuclein pathology may contribute to non-motor deficits in PD is 
supported by experimental evidence that mouse models of α-synuclein over-expression 
display deficits in behaviors also affected in early PD (Chesselet et al., 2012; Hatami 
and Chesselet, 2015; Magen and Chesselet, 2011). This has been extensively 
characterized in mice over-expressing α-synuclein under the Thy1 promoter developed 
by Eliezer Masliah (Thy1-aSyn mice; line 61) (Rockenstein et al., 2002). These mice 
express human wild-type α-synuclein at 2-4-fold higher levels than endogenous α-
synuclein and exhibit broadly distributed α-synuclein aggregates throughout the brain. 
They also exhibit extensive behavioral deficits in many domains affected in pre-manifest 
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PD, including cognition, sleep, social interaction and autonomic function, as well as 
inflammation, mitochondrial dysfunction, and later loss of striatal dopamine. Thus, α-
synuclein line 61 mice recapitulate many aspects of sporadic PD (Chesselet et al., 
2012; Magen et al., 2015; McDowell et al., 2014; Subramaniam et al., 2014). 
 
In previous studies (Magen et al., 2012), we have detected a decrease in acetylcholine 
in the cortex of Thy1-aSyn mice at an age when cognitive deficits were present, 
suggesting that α-synuclein pathology is sufficient to induce acetylcholine deficits 
analogous to those reported in PD patients (Pfeiffer et al., 2014; Yang et al., 2016; 
Zarow et al., 2003). Cholinesterase inhibitors are clinically used for cognitive deficits in 
PD patients, on the assumption that the inhibitors primarily exert any therapeutic effects 
by inhibiting the hydrolysis of acetylcholine to choline; but these drugs show limited 
efficacy (Emre et al., 2004; Grace et al., 2009; Hanagasi et al., 2017; Mamikonyan et 
al., 2015; Wang et al., 2015). Stimulating nicotinic receptors may be a better approach 
to treat cognitive disorders in a variety of disorders (Gee et al., 2017; Harris et al., 2004; 
Preskorn et al., 2014; Wallace and Porter, 2011). However, there is little preclinical 
information on the ability of nicotine to improve deficits due to α-synuclein pathology as 
present in PD or other synucleinopathies.   
 
In the current study we use the Thy1-aSyn mouse model to test the hypothesis that 
chronic nicotine administration could improve deficits in cognition and social behavior 
induced by α-synuclein pathology. The aim of this study was to provide preclinical data 
to support or invalidate the development of nicotinic agents to treat aspects of PD. We 
administered nicotine subcutaneously by osmotic minipump either for either 6 months 
(2-8 months of age) or one month (5-6 months of age) to male Thy1-aSyn mice and 
measured their performance in tests of cognition and social interaction. In addition, 
because previous studies in toxin-induced animal models of dopamine degeneration 
have proposed a protective role of nicotine in PD (Costa et al., 2001; Picciotto and Zoli, 
2008; Quik et al., 2012; Ryan et al., 2001; Toulorge et al., 2011), we assessed the 
effects of nicotine administration on early motor deficits and α-synuclein pathology in 
these mice. The results show that chronic nicotine administration improves cognitive 
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and social impairments without affecting motor deficits or α-synuclein aggregates in 
Thy1-aSyn mice.  
 
Materials and Methods 
 
Animals  
Mice over-expressing human, full length, wild type (Wt) α-synuclein under the murine 
Thy1-promoter (Thy1-aSyn mice) were developed at the laboratory of Dr. E. Masliah 
(University of California, San Diego) (‘line 61’’ of (Rockenstein et al., 2002). Thy1-aSyn 
mice were maintained on a hybrid C57BL6/DBA2 background as described previously 
(Fleming et al., 2004; Rockenstein et al., 2002). The genotypes of all Thy1-aSyn and Wt 
mice were determined at 1 month of age and confirmed at the end of the experiment by 
polymerase chain reaction (PCR) amplification analysis of tail DNA. We studied male 
mice to maintain gene dosage, because the transgene is inserted in the X chromosome 
in this line. Transgenics and their Wt littermates were distributed among the study 
groups to avoid any litter effect, and the group sizes were determined based on our 
power analysis (Chesselet et al., 2012). Animals were socially housed ≤ 4 in each cage 
and maintained on a reverse light/dark cycle to facilitate behavioral analysis. Mice were 
housed on standard bedding (shredded wood) and material for nest-building (Nestlets, 
Ancare, NY, USA) was provided. Mice had ad libitum access to water and standard 
rodent diet (NIH-31 modified 7013, Harlan). Room temperature in the mouse holding 
room was 23 ± 2°C and relative humidity was ~60%; values were recorded during the 
daily animal check. Animal care complied with the United States Public Health Service 
Guide for the Care and Use of Laboratory Animals and all experimental procedures 
were approved by the UCLA Institutional Care and Use Committee.  
 
Nicotine administration: first (“six-month”) cohort 
Two separate cohorts of male mice were used (Fig. 1). A first cohort was treated with 
nicotine for 6 months. Thy1-aSyn mice were divided into three groups (minimum of n=20 
per group) and treated with vehicle (saline; Teknova, USA; #S5819) supplemented with 
either zero, 0.4, or 2.0 mg/kg/h nicotine (calculated as the free base, prepared from 
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nicotine tartrate, Sigma, USA; #N5260). A fourth group, Wt littermates (minimum of 
n=20), were treated with vehicle plus zero nicotine, serving as additional controls. 
Treatment began at 2 months of age. Solutions could be infused subcutaneously for one 
month using implanted osmotic minipumps (Alzet, USA; Model 2004). Briefly, vehicle, 
with or without nicotine, was loaded into the minipump and maintained at 37oC for 48 h 
before the implantation surgery. For the initial implant surgeries (at 2 months), mice were 
anesthetized with isoflurane. A subcutaneous pocket was created in the dorsal thoracic 
area and received the minipump. Mice treated with the higher nicotine dose (2.0 mg/kg/h) 
lost weight after this surgery; 50% died after one week. Because the toxicity in the high 
dose nicotine (2.0 mg/kg/h) group might have been due to the combined toxic effects of 
isoflurane and a higher dose of nicotine, we used pentobarbital instead of isoflurane for 
induction of anesthesia for subsequent surgeries in this cohort. Briefly, anesthesia was 
induced with pentobarbital (6.6 mg/kg, i.p.) and a surgical level of anesthesia was 
maintained with isoflurane (0.5-1.5% in O2). The use of combined pentobarbital and 
isoflurane markedly reduced the mortality rate and improved weight gain in the higher 
dose group. At one month intervals, fresh osmotic mini-pumps were loaded with nicotine 
solutions adjusted for body weight, and were implanted at the same subcutaneous 
pocket.  
 
For this cohort, we intended to treat for 6 months. The full time course was achieved for 
the lower nicotine dose of 0.4 mg/kg/h. However, Thy1-aSyn mice treated with the higher 
nicotine dose, 2.0 mg/kg/h nicotine, died at an unexpectedly high rate: 50% mortality was 
observed in this group after four months of nicotine administration. We minimized pain 
and suffering by euthanizing the remaining members of the Thy1-aSyn higher dose group 
at 6 months of age (4 months of treatment). It must be noted that a few mice (n=3) in the 
higher dose group completed full time course of treatment before a decision was made to 
shorten their treatment. 
 
Nicotine administration: second (“one-month”) cohort 
Experience gained with the first cohort allowed us to minimize animal use, pain, and 
suffering in a second cohort. Treatment began at 5 months of age. We used the 
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pentobarbital-isoflurane anesthesia protocol. Thy1-aSyn mice and their Wt littermates 
were divided into two groups each (minimum of n=20 per group) and received either 
vehicle or the lower nicotine dose, 0.4 mg/kg/h. Each mouse received a single minipump, 
for a single month of treatment.  
 
For both the first (six-month) and the second (one-month) cohort, general health was 
monitored daily. Body weights were monitored and recorded daily for a week after implant 
surgery and twice weekly thereafter. Mice receiving the lower nicotine dose (0.4 mg/kg/h) 
showed no differences in general health compared to mice administered with vehicle. 
Above, we summarize health issues in the first cohort, exposed to 2.0 mg/kg/h nicotine. 
 
Behavioral testing 
 
All behavioral testing was performed (Fig. 1) and analyzed by investigators without 
knowledge of genotype and drug treatment. Body weights were recorded before the 
behavioral tests to control for any confounding effects of differences in weight on 
measures of activity. Motoric behavior was tested in only the six-month treatment cohort, 
once before treatment at 2 months (pre-treatment) and then at 4 (Post 1), 6 (Post 2) and 
8 months (Post 3) of age, on the challenging beam and the vertical pole as described 
previously (Fleming et al., 2004). Briefly, for challenging beam test, each mouse was 
trained on a narrowing horizontal beam for two days and tested on third day using the 
same narrowing horizontal beam but with grids placed on it for 5 trials. For the vertical 
pole test, each mouse was trained for two days to turn and climbdown the vertical pole 
without falling, and tested on third day for 5 trials. Each mouse was also tested for 
general locomotor activity in the open field (15 min) at 5 months of age and 8 months of 
age as described previously (Lam et al., 2011; Wang et al., 2012).  
 
Cognitive behavior testing was performed in the six-month treatment cohort mice at ages 
5 months and 7 months (Y-maze spontaneous alternations). In one-month treatment 
cohort novel object recognition and social behavior tests was performed at 6 months of 
age. 
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Y-maze spontaneous alteration and novel object recognition were assessed as described 
previously (Magen et al., 2012). Briefly, mice were allowed to explore the Y-maze for 7 
min, while the visits to each arm were counted. Successive visits to the three different 
arms were considered as an alternation and percentage of spontaneous alternations were 
calculated as alternations/(arm entries-2)*100 – 50% to set chance level at zero. Mice 
which had < 7 visits in the 7-minute tested period were excluded from analysis as non-
performers, slightly modified from (Lelong-Boulouard et al., 2006), who set the exclusion 
criteria at 5 visits for 5 min. 
 
For novel object recognition (NOR) test, mice were first habituated to the cylindrical tank 
for 5 min the day prior to the testing day. On the testing day mice were exposed to two 
identical objects (pig or wolf figurines) for 10 min and after a 30-40 min interim interval 
one of the objects was replaced with a novel object. During exploration, the mice were 
videotaped, and later analyzed in a blinded fashion. The objects were balanced among 
different mice to avoid any object preference bias. Mice with total exploration time of < 7 
s, indicating low interest in the objects, were excluded from all further analyses (de Bruin 
and Pouzet, 2006). The discrimination index was defined as DI = (N - F) / (N + F), where 
N and F represents total time spent exploring the novel and familiar objects, respectively. 
 
The social approach task was performed in only the one-month treatment cohort at 6 
months of age as described before (Magen et al., 2015). Briefly, mice were first 
habituated to the center chamber of a three-chamber Perspex® apparatus with the two 
side chambers closed, for 10 min on the testing day (phase I). Thereafter, the doors 
connecting the chambers were opened and the mice were now allowed to explore all 
three chambers for 10 min (phase II). In the final phase of the test (phase III), an empty 
1 L glass beaker was placed in one of the side chambers whereas the same beaker 
containing a novel mouse from the 129Sv strain was placed in the other side chamber. 
Locations of empty beaker and beaker containing a mouse were balanced to avoid 
potential confounding effect of baseline side preference. Mice were allowed to explore 
all three chambers as in phase II. The time spent in the side chambers in phase III was 
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recorded during testing, while the sniffing times at the empty beaker and at the beaker 
containing the mouse were measured from video recordings by a blinded observer.   
 
Euthanasia and immunohistology 
The measurement of pathological endpoints by immunohistology was performed in only 
the six-month treatment cohort. After the treatment phase, 50% of the mice (n=10) from 
each group were anesthetized with pentobarbital, perfused shortly with PBS and then with 
4% paraformaldehyde. Their brains were processed for histological analysis. Because the 
nicotine treatment in the higher dose group was terminated early (at 6 months of age), the 
immunohistology results for this group were obtained in 6-month old mice.  
 
Brain sections from the Wt and each transgenic group were reacted for α-synuclein with a 
mouse (anti-human and anti-mouse) α-synuclein monoclonal antibody (BD Transduction 
Laboratories, USA, 610787) at 1:250 dilution, for tyrosine hydroxylase with rabbit 
monoclonal anti-TH antibody (Millipore, USA; AB152) at 1:600 dilution, for synaptophysin 
with mouse monoclonal anti-synaptophysin antibody (Millipore, USA; MAB5258) at 
1:2000 dilution, and for microtubule-associated protein 2 (MAP2) with rabbit polyclonal 
anti-MAP2 antibody (Millipore, USA; AB5622 at 1:500 dilution). Secondary antibodies 
conjugated with Alexa 488 or Alexa 594 were used for immunofluorescence labeling and 
quantified as described previously (Richter et al., 2014a). For the assessment of α-
synuclein aggregates, the sections were treated with proteinase K and quantified as 
described previously (Fernagut et al., 2007; Fleming et al., 2011; Richter et al., 2014a). 
Microglial activation was quantified in SN using rabbit polyclonal antibody against ionized 
calcium binding adaptor molecule (anti-Iba-1) (Wako, Osaka, Japan, #019-19741, at 
1:500 dilution) as described (Watson et al., 2012). All analyses were performed by 
investigators unaware of genotype and treatment groups.  
 
Statistics 
Statistical analysis was performed with SigmaPlot software (v. 12.0, Systat Inc., USA). 
For the analysis of the 6-month treatment cohort: (1) two-tailed Student’s t-test (when 
data were homoscedastic) or Mann Whitney U-test (when data were heteroscedastic) 
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were used to compare Wt-vehicle and Thy1-aSyn-vehicle groups for genotype 
differences, (2) Analysis of variance (ANOVA) was used to compare the nicotine 
treatment effect in Thy1-aSyn groups, followed when appropriate with post hoc 
Bonferroni t-tests versus control (Thy1-aSyn-vehicle) group. For the analysis of 1-month 
treatment cohort, two-way ANOVA followed by post hoc Bonferroni t-tests were used. 
Data were tested for equal variances prior to ANOVA. In addition, for cognitive tests the 
data were compared to chance level (zero) by using one-sample t-test. A paired t-test 
was used to compare the effect on same groups at different timepoints. Outliers in all 
the analysis were excluded with Grubb’s outlier test. The investigator was blinded to the 
groups when assessing the outcome of the experiments. 
 
Results 
 
Nicotine effects on Y-maze alternation 
 
Spontaneous Y-maze alternation test was performed at 5 and 7 months of age (3 and 5 
months of nicotine or vehicle administration, respectively). The Thy1-aSyn-vehicle 
group performed significantly worse at 7 than at 5 months (paired t-test, t20=2.18, 
p=0.04) (Fig. 2). No significant performance deficit was noted in the Wt-vehicle mice. 
These data indicate the development of cognitive deficits with age in the Thy1-aSyn 
mice, consistent with previous results (Magen et al., 2012).  
 
Because several mice died between 5 and 7 months of age, we analyzed the data at 
each time point separately. At 5 months of age (Fig. 2), all groups displayed significantly 
more alternations than the chance level of zero percent (p<0.05, one-sample t-test), 
indicating intact alternation behavior and spatial memory. At 7 months of age, Wt-
vehicle mice but not Thy1-aSyn-vehicle mice maintained this significantly higher than 
zero alternation percentage (one-sample t-test, p=0.02 and 0.77, respectively), 
indicating that Y-maze performance was impaired in Thy1-aSyn mice, as previously 
reported for that age (Magen et al., 2012). In contrast, Thy1-aSyn mice administered 0.4 
mg/kg/h nicotine performed above chance (p=0.04), at the same level as Wt-vehicle 
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mice, indicating that nicotine substantially reverses this impairment (Fig. 2). The total 
number of entries did not differ between the groups at any time point, indicating a 
similar level of activity (data not shown). The data indicate that 5 months of nicotine 
administration at 0.4 mg/kg/h improve cognitive performance, as tested by Y-maze 
alternation.  
 
Thy1-aSyn mice treated with 2.0 mg/kg/h nicotine also displayed significantly higher 
than zero alternation percentage at 7 months. However, only three mice completed the 
full course of 6 months treatment (see methods). 
 
Previous studies on Thy1-aSyn mice showed small deficits in the Y-maze at 5-6 months 
of age (Magen et al., 2012) but the magnitude of the deficit was much smaller than at 7-
9 months of age, when an effect was also observed in the six-months treatment cohort 
in the present study. Similarly, in the one-month treatment cohort, ANOVA revealed no 
main effect of either genotype (F1,69=0.715, p=0.4) or 0.4 mg/kg/h nicotine treatment 
(F1,69=0.43, p=0.51), and also no interaction effect (F1,69=0.035, p=0.85). The 
percentage of spontaneous alternations for the groups are as follows: Wt-vehicle: 
3.43±3.21%, n=19; Thy1-aSyn-vehicle: 6.92±3.92%, n=13; Wt-0.4 mg/kg/h nicotine: 
1.84±3.38%, n=18; Thy1-aSyn-0.4 mg/kg/h nicotine: 4.07±3.15%, n=21 (Mean ± SEM).  
 
Nicotine effects on NOR 
 
In contrast to previous results obtained in naïve mice (Magen et al., 2012), we observed 
no deficit in NOR performed in the six-month treatment cohort at 7 months of age (after 
5 months of nicotine or vehicle administration). The groups had discrimination index 
values as follows: Wt-vehicle: 0.1±0.08, n=18; Thy1-aSyn-vehicle: 0.08±0.08, n=18; 
Thy1-aSyn-0.4 mg/kg/h nicotine: 0.11±0.08, n=15; Thy1-aSyn-2.0 mg/kg/h nicotine: 
0.29±0.21, n=3 (Mean ± SEM). Total exploration times of the objects did not differ 
between the groups, consistent with previous data (Magen et al., 2012). It is possible 
that the repeated surgeries and behavioral testing have led to altered performance in 
both Wt/vehicle and the Thy1-aSyn/vehicle groups, which were much lower than those 
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previously observed in naïve mice (Magen et al., 2012) (and see below), thus impairing 
detection of a deficit in the transgenics. 
 
In the one-month cohort tested for NOR, we administered the lower nicotine dose (0.4 
mg/kg/h) to 5-month-old mice for only one month. In contrast to the 6-month cohort, 
which received multiple surgeries and behavioral testing, vehicle-treated Thy1-aSyn 
mice in this one-month cohort showed a significant deficit in NOR at 6 months of age 
compared to vehicle-treated Wt littermates, and this deficit was reversed in mice that 
received 0.4 mg/kg/h of nicotine (Fig. 3). The groups displayed DI values as follows 
(Mean ± SEM): Wt-vehicle: 0.28±0.11, n=17; Thy1-aSyn-vehicle: 0.00±0.09, n=12; Wt-
0.4 mg/kg/h nicotine: 0.11±0.09, n=17; Thy1-aSyn-0.4 mg/kg/h nicotine: 0.23±0.07, 
n=19. Two-way ANOVA revealed no main effect of genotype (F1,59=0.677, p=0.414) or 
of treatment (F1,59=0.103, p=0.750) but showed an interaction effect (F1,59=4.35, 
p=0.042). The Wt-vehicle mice, but not the Thy1-aSyn-vehicle mice, displayed 
discrimination indices significantly higher than zero (p=0.027 vs p>0.99, respectively, 
one-sample t-test). In contrast, Thy1-aSyn/0.4 mg/kg/h nicotine mice performed 
significantly higher than zero (p=0.006) (Fig. 3). Thus, NOR performance was impaired 
in Thy1-aSyn mice, extending previous data at the earlier time of 4-5 months (Magen et 
al., 2012). Importantly, the present data show that treatment with 0.4 mg/kg/h nicotine 
for one month completely reversed this impairment. Unexpectedly, however, nicotine 
impaired performance in Wt mice, which no longer performed above chance level 
(p=0.25). 
 
Nicotine effects on social behavior 
 
In our previous studies, we detected a deficit in a social approach task in Thy1-aSyn 
mice, suggesting a deficit akin to the impairment of theory of mind described in PD 
patients (Magen et al., 2015). This task was performed in the one-month nicotine 
treatment cohort at 6 months of age. As described in methods, we compared sniffing 
times at an empty beaker versus a beaker containing a mouse from another genetic 
background after appropriate habituation. Results in Wt mice revealed the expected 
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strong preference for the beaker containing a mouse, whereas this preference was 
decreased in Thy1-aSyn mice receiving vehicle, confirming our previous data (Fig. 4). 
Repeated measure ANOVA with group as between-subject factor and variable (i.e. 
empty beaker vs. beaker with a mouse) as a within-subject factor revealed no main 
effect of group (F3,148=2.164, p=0.1) or interaction effect between group and variable 
(F3,148=0.603, p=0.615) but did reveal an effect for the sniffed item (F1,150=41.76, 
p<0.001). The two Wt groups showed a significant preference for exploring a beaker 
with a novel mouse over exploring an empty beaker (p<0.001), whereas the Thy1-
aSyn/vehicle group showed no such preference (Bonferroni post-hoc test). Furthermore, 
Thy1-aSyn-vehicle mice sniffed a beaker with a novel mouse to a lesser extent than 
Wt/vehicle mice (p=0.044). Treatment with 0.4 mg/kg/h nicotine completely restored the 
preference for the mouse versus empty beaker in Thy1-aSyn mice (p<0.001). 
Comparing chamber time between the groups revealed no main effects (p>0.05) 
indicating that the mice had no preference for either chamber, an important control. The 
results confirm our previous findings (Magen et al., 2015) that Thy1-aSyn mice have a 
decreased interest in social stimuli compared to Wt mice while they explore a neutral, 
inanimate object to the same extent, indicating social cognition impairment rather than 
general exploratory deficit. This impairment was reversed by 0.4 mg/kg/h nicotine 
administration.  
 
Chronic nicotine treatment did not improve motor deficits in challenging beam and 
vertical pole tests 
 
To evaluate the effect of nicotine treatment on α-synuclein-induced motor deficits, we 
tested the mice in the challenging beam and vertical pole tests at four time points 
including pre-treatment time point (2 months), and at 3 time points during nicotine 
administration called Post 1 (4 months), Post 2 (6 months) and Post 3 (8 months). Motor 
deficits in these challenging tests are robust and appear as early as 2 months in the 
Thy1-aSyn mice (Chesselet et al., 2012; Fleming et al., 2004). These deficits are distinct 
from parkinsonism, which occurs at much older ages when the Thy1-aSyn mice begin to 
show decreased striatal dopamine (Lam et al., 2011). They reflect impairment in 
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nigrostriatal (Lam et al., 2011) and/or extranigral (Watson et al., 2009; Wu et al., 2010) 
circuits resulting from α-synuclein overexpression. Deficits in the challenging beam were 
confirmed in this study in 2-month-old transgenic mice, which show a large increase in 
number of errors per step (Fig. 5A) (Fleming et al., 2004). As previously reported, this 
motor deficit progressed between 2 and 8 months of age in the Thy1-aSyn mice (Fig. 5B).  
 
Administration of neither the lower (0.4 mg/kg/h, 6 months) nor the higher (2.0 mg/kg/h, 4 
months) nicotine dose, improved this motor deficit (Fig. 5A). To evaluate the effect of 
nicotine on the progression of beam deficits, we calculated the difference between the 
numbers of errors per step at each time point for each mouse. Thy1-aSyn mice show a 
significant worsening at 4 months compared to 2 months of age; this was not significantly 
affected by nicotine (Fig. 5B), despite the good power conferred by using relatively large 
groups of mice. The deficit on the beam leveled off at later time points; and again, 
nicotine had no effect.  Thus, nicotine administration did not significantly improve deficits 
on the challenging beam when administered after this motor deficit was already 
established.  
 
In the vertical pole, a test of balance and coordination, Thy1-aSyn mice take longer than 
Wt mice to turn around and descend the pole (Fig. 6A) (Fleming et al., 2004). Nicotine 
treatment, 0.4 mg/kg/h (for 6 months) and 2.0 mg/kg/h (for 4 months), did not improve this 
motor deficit at any time point tested (Fig. 6A). About 50% of the Thy1-aSyn mice were 
able to perform this task within the time limit at 2 months of age but only 25% at 4 months 
and almost none at later ages. Nicotine did not affect the number of mice able to perform 
the task (Fig. 6B). These results indicate that chronic nicotine administration failed to 
improve the progressive motor deficits observed in Thy1-aSyn mice, even after 6 months 
of continuous treatment.  
 
Chronic nicotine treatment did not alter hyperactivity in the open field  
 
Locomotor activity in open field was examined at 5 months (3 months of nicotine 
treatment) and 8 months (6 months of nicotine treatment) of age. We measured move 
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episodes, total move time, move time per episode, total distance traveled, distance 
traveled per episode, movement velocity, center entries, and rearings. Previous studies 
by our group showed hyperactivity in relatively young (4-7 months of age) Thy1-aSyn 
mice (Lam et al., 2011; Wang et al., 2012). This observation was confirmed in the present 
cohort (Table 1): Thy1-aSyn mice receiving vehicle showed a decrease in move episodes 
(p<0.01) and an increase in move time per episode (p<0.001), as well as the other 
parameters measured, indicating hyperactivity compared to Wt vehicle treated mice at 
both time points. Several lines of transgenic mice over-expressing α-synuclein show 
hyperactivity at early ages (Chesselet et al., 2012) and we have previously attributed this 
hyperactivity to increased extracellular dopamine in the striatum of young Thy1-aSyn 
mice (Lam et al., 2011). Administration of nicotine at two doses, 0.4 mg/kg/h and 2.0 
mg/kg/h, for 3 months and 6 months produced no change in hyperactivity of the mice 
(Table 1).  
 
Lack of chronic nicotine effects on histological parameters in Thy1-aSyn mice  
 
A hallmark of sporadic PD is the accumulation of Lewy bodies or Lewy neurites, 
containing α-synuclein.  Similar to other transgenic models, Thy1-aSyn mice do not 
show mature fibrillar structures identical to Lewy bodies but do show proteinase K-
resistant aggregates of α-synuclein. Although the role of α-synuclein aggregates in 
neurotoxicity remains unclear, decreased α-synuclein levels have been associated with 
functional improvement in the model studied here (Richter et al. 2014). To assess the 
effects of nicotine treatment on the α-synuclein levels in brain, we measure α-synuclein 
immunofluorescence in the substantia nigra (SN). Regional measurement of the 
immunofluorescence intensity in the SN showed a significant increase in α-synuclein 
levels in Thy1-aSyn mice in the SN pars compacta. Nicotine treatment at 0.4 mg/kg/h 
(for 6 months) or at 2.0 mg/kg/h (for 4 months) did not alter the levels of α-synuclein in 
SN of Thy1-aSyn mice. Similarly, nicotine treatment did not modify the α-synuclein 
aggregate load in Thy1-aSyn mice (Table 2). 
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To ensure that nicotine administration did not have detrimental effects on synaptic and 
dendritic markers in the striatum, we analyzed the levels of synaptophysin (a major 
presynaptic vesicle protein) and MAP2 (a dendrite-specific microtubule-associated 
protein) by immunohistochemistry in 8-month-old Thy1-aSyn mice (6 months after the 
start of treatment). Confirming previous results, vehicle-treated Thy1-aSyn mice showed 
unchanged synaptophysin or MAP2 levels compared to Wt mice, and nicotine did not 
affect these parameters (Table 2). 
 
Confirming our previous observation that tyrosine hydroxylase (TH) loss occurs 
beginning at 14 months of age in Thy1-aSyn mice (Lam et al., 2011), we found 
unchanged TH immunoreactivity in Thy1-aSyn mice compared to Wt mice; and nicotine 
treatment did not affect TH levels in the SN or striatum (Table 2), indicating a lack of 
toxicity on dopaminergic terminals.  
 
To determine the effect of nicotine administration on inflammation in Thy1-aSyn mice, 
we measured the levels of activated microglia in SN of mice using Iba-1, a microglial 
marker. Based on our previous observations, resting microglia are 1 to 4 µm in diameter 
whereas activated microglia are >6 µm in diameter. We previously observed a microglial 
activation in 5-6 months old Thy1-aSyn mice together with an increased production of 
pro-inflammatory cytokines (Watson et al., 2012). Wt mice had a markedly lower level of 
microglial activation in this study compared to our previous studies (Richter et al., 
2014a; Watson et al., 2012), suggesting an overall lower level of inflammation in the 
present cohort, possibly related to general improvements in husbandry. In contrast to 
our previous observations in younger, 5-6 month-old mice (Watson et al., 2012), we did 
not observe any microglial activation in vehicle-treated 8-month-old Thy1-aSyn mice 
compared to Wt mice (Fig. 7A), consistent with our findings that α-synuclein over-
expressing mice have only transient microglial activation (Watson et al., 2012). Nicotine 
administration induced no change in microglial activation in Thy1-aSyn mice (Fig. 7B, 
7C).  
 
Discussion 
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In the present study we investigated the effects of sustained administration of two doses 
of nicotine for six months on tests of motor and cognitive function, as well histological 
markers, in a genetic model of pre-manifest PD (Chesselet et al., 2012). We further 
examined the effects of a sustained administration of the safer nicotine dose for one 
month on cognitive and social behaviors in these mice. Chronic nicotine administration 
improved synuclein-induced cognitive and social impairments in young Thy1-aSyn mice, 
but benefited neither early motor deficits, nor alterations in the levels of overexpressed 
human α-synuclein protein, nor its proteinase-K resistant aggregates in the SN.  
 
Pre-manifest deficits in Thy1-aSyn mice 
We conducted our study in Thy1-aSyn mice (line 61)(Rockenstein et al., 2002) because 
these mice offer a well characterized model of pre-manifest PD that has now been used 
in several laboratories for preclinical studies of potential disease modifying treatment 
(Lee et al., 2011; Magen et al., 2014; Richter et al., 2014a; Richter et al., 2014b; 
Wrasidlo et al., 2016). Beginning at an early age, these mice exhibit cognitive decline 
(Magen et al., 2012) and other non-motor deficits (Chesselet et al., 2012; Fleming et al., 
2008; McDowell et al., 2014; Subramaniam et al., 2014), reminiscent of defects 
observed in the pre-manifest phase of PD. The Thy1-aSyn mice show hyperactivity 
when young, and elevated extracellular dopamine at 6 months of age (Lam et al., 2011). 
Interestingly, elevated striatal dopamine occurs in vivo in pre-symptomatic human 
carriers of LRRK2 mutations, a cause of familial PD (Sossi et al., 2010). In contrast, the 
Thy1-aSyn mice of line 61 develop parkinsonism with loss of striatal dopamine and L-
dopa-responsive deficits at a relatively late age, 14 months (Lam et al., 2011).  
 
We note previous reports that the phenotype of this model differs in some respects from 
other α-synuclein over-expressing lines constructed with portions of the same mouse 
Thy-1 promoter, and with various α-synuclein mutants. These differences include both 
the cell types that show abnormalities and the behavior. Phenotypic differences among 
these strains may arise from the pathophysiology of the mutant, the detailed sequence 
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of the promoter fragment used, the insertion locus, and the host mouse strain 
(Chesselet and Richter, 2011) (http://jaxmice.jax.org/strain/017682.html). 
 
The present study confirms previous findings that the Thy1-aSyn mice show deficits in 
cognitive function (Magen et al., 2012), accompanied neither by striatal dopamine loss 
(Lam et al., 2011) nor by changes in TH immunoreactivity (Fernagut et al., 2007). 
Performance on several of these cognitive tests depends on the integrity of cortical 
neurotransmission involving acetylcholine. Such systems are typically termed 
“cholinergic”, typically meaning actions of acetylcholine on either nicotinic acetylcholine 
receptors (nAChRs) or muscarinic receptors. In some brain regions, nicotinic α7 
receptors may also be activated by circulating levels of choline itself, another 
eponymous cholinergic transmitter. As one example of a muscarinic cognitive effect, 
spontaneous alternations in Y-maze and NOR are impaired by the administration of a 
muscarinic antagonist, scopolamine (Barker and Warburton, 2009; Botton et al., 2010; 
Wall and Messier, 2002). Interestingly, the levels of cortical acetylcholine were 
decreased at 6 months of age in Thy1-aSyn mice (Magen et al., 2012) suggesting that 
the deficits in Y-maze and NOR observed in our study may be due to cholinergic 
deficits. It is important to note that cholinergic systems in PD patients can be impaired 
by Lewy body pathology (Braak et al., 2003) and cholinergic cell loss (Zarow et al., 
2003) in the basal nucleus of Meynert. PD patients display reduced nAChRs and 
cholinergic denervation (Bohnen and Albin, 2009; Bohnen et al., 2015; Fujita et al., 
2006; Meyer et al., 2009), and this may be associated with mild cognitive and 
depressive symptoms. Also, up to 50% reduction in the nAChR levels are reported in 
PD patients especially in frontal and temporal areas that are involved in memory, 
learning and stimulus-seeking behaviors (Hershey and Perlmutter, 2014; Quik and 
Jeyarasasingam, 2000). In Thy1-aSyn mice, human α-synuclein accumulates in 
cholinergic neurons of the basal nucleus of Meynert as early as 5 months of age 
(Magen et al., 2012).  
 
Brain cholinergic systems are vital for various cognitive functions including memory, 
learning and attention (Everitt and Robbins, 1997), involving several regions of the 
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brain, in both primates and rodents. nAChRs occur widely in neocortical and subcortical 
areas (Perry et al., 1992; Poorthuis et al., 2009). Evidence indicate that there is 
significant reduction of cortical nAChRs in post-mortem brains of both demented and 
non-demented PD patients (Oishi et al., 2007; Pimlott et al., 2004; Rinne et al., 1991). 
Previous studies from our group implies that chronic nicotine exposure upregulates 
some nAChRs (Henderson and Lester, 2015; Lester et al., 2009). Upregulated nAChRs 
include α4β2* and α6* (*indicating other subunits may be present) (Henderson et al., 
2014; Lester et al., 2009; Srinivasan et al., 2014). Previous evidence for a decrease in 
choline acetyl transferase in Thy1-aSyn mice (Magen et al., 2012) together with the 
current profound effect of chronic nicotine administration on cognitive deficits, at a time 
when no dopaminergic deficit can be detected in this model, supports the hypothesis 
that the defects in cholinergic rather than dopaminergic systems in the Thy1-aSyn mice 
might have caused the cognitive impairment. Future studies should be directed at 
determining whether this impairment was improved by chronic nicotine treatment via 
upregulation of nAChRs in addition to direct stimulation of these receptors, as 
suggested by our previous work (Henderson and Lester, 2015; Henderson et al., 2014; 
Lester et al., 2009; Srinivasan et al., 2014).  
 
In addition to cognitive deficits, Thy1-aSyn mice display impairments in social behaviors 
(Magen et al. 2015), and these were improved by nicotine administration. Impaired 
social behavior in humans is characterized by deficits in non-verbal expression and in 
social approach, abnormalities in social use or understanding of language, or markedly 
diminished peer relationships (Moy et al., 2004). Social interactions of PD patients may 
be affected by disrupted social connectedness (Soleimani et al., 2014); PD patients with 
mild cognitive deficits showed impairment in social behavior (Anderson et al., 2013). As 
mentioned, nicotine and other nicotinic agonists activate several nAChR subtypes which 
are involved in social behavior in monkeys and rodents (Bitner et al., 2010; Boess et al., 
2013; Feuerbach et al., 2009; Henderson and Lester, 2015; Salas et al., 2013; Sarter et 
al., 2009; Timmermann et al., 2012). Chronic nicotine treatment also benefited social 
behavior in G72Tg mice, a possible mouse model of schizophrenia (Hambsch et al., 
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2014). Hence, the observed improvement in social impairment by nicotine in Thy1-aSyn 
mice might be related to nAChR upregulation. 
 
Previously reported early α-synuclein-induced motor deficits and hyperactivity (Fleming et 
al., 2004; Lam et al., 2011) were also observed in the current study. These highly 
reproducible phenotypes confer good power to detect drug effects (Chesselet et al., 
2012), rendering this mouse model reliable and robust for pre-clinical drug efficacy 
studies (Fleming et al., 2011; Magen et al., 2014; Richter et al., 2014a; Richter et al., 
2014b). However, chronic nicotine administration did not ameliorate the motor deficits or 
hyperactivity phenotype in the Thy1-aSyn mice. This is unlikely due to the severity of the 
deficit, because other compounds improve these deficits in mice of approximately the 
same age as in the present study (Richter et al., 2014b; Wrasidlo et al., 2016). The use of 
chronic administration of nicotine in this study adds to previous evidence obtained with 
more acute administration of nicotine or nAChR agonists that also did not improve motor 
deficits in models of PD as reviewed in (Quik et al., 2015).  
 
Similarly, our results showed that nicotine administration did not alter the levels of α-
synuclein in the SN and striatum of Thy1-aSyn mice, nor the level of proteinase K 
resistant α-synuclein aggregates in SN. This suggests that in our experimental conditions, 
nicotine did not markedly modify the production, clearance or aggregation of human α-
synuclein in vivo. In vitro, nicotine, at concentrations at least 100-fold greater than those 
produced in mouse brain by our treatments (Nashmi et al., 2007) prevented the fibrillation 
of purified α-synuclein (Hong et al., 2009; Ono et al., 2007). These effects of nicotine on 
purified α-synuclein are irrelevant to any form of human nicotine use. Together our 
findings highlight the inability of chronic nicotine treatment to improve early α-synuclein-
induced motor deficits or pathology in a pre-manifest mouse model of PD, thus providing 
no support for a neuroprotective effect of nicotine. 
 
Many case-control epidemiological studies demonstrate an inverse relationship between 
smoking and PD risk (Gorell et al., 1999; Tanner et al., 2002), and the risk of PD in 
someone who has ever smoked is about half of that of a non-smoker (Checkoway et al., 
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2002; Sugita et al., 2001). Nicotine has been a strong candidate for tobacco constituent 
responsible for the apparent neuroprotective effect of smoking, because in animal 
models, nicotine has neuroprotective effects against toxin-induced loss of nigrostriatal 
dopaminergic neurons (Costa et al., 2001; Khwaja et al., 2007; Quik et al., 2013; Quik et 
al., 2012). Nicotine may protect dopaminergic neurons against apoptosis by decreasing 
endoplasmic reticulum stress and the unfolded protein response (Srinivasan et al., 2016). 
However, toxin-induced models may lack predictive value for neuroprotection because 
they do not reproduce the pathophysiology that leads to widespread neuronal dysfunction 
and dopaminergic cell loss in PD. Furthermore, recent epidemiological studies question 
the interpretation of the relationship between PD and smoking (Hershey and Perlmutter, 
2014; Ritz et al., 2014). Based on evidence that individuals in early stages of PD quit 
smoking much more easily than controls, Ritz and colleagues (2014) suggested that the 
lower number of smokers in the PD group occurs because nicotine loses its reinforcing 
properties in early PD, rather than nicotine protecting the neurons. Accordingly, the 
neuroprotective properties of nicotine in PD remain unproven. Previous clinical trials have 
failed to show any beneficial effect of short-term nicotine administration in PD patients 
(Clemens et al., 1995; Vieregge et al., 2001). Chronic nicotine treatment in PD patients 
has been confirmed to be safe and tolerable (Villafane et al., 2007) but its neuroprotective 
effect awaits the results of ongoing clinical trials that are examining transdermal nicotine 
patches (NCT01560754) in PD. Varenicline, a nicotinic agonist, is also currently under 
clinical trials (NCT02473562, NCT02933372, NCT01341080) for PD therapy. 
 
Conclusion 
Our results suggest that chronic administration of nAChR agonists may improve cognitive 
and social deficits, debilitating non-motor aspects of early PD. Although not supported by 
the results of this study, this does not exclude a possible neuroprotective effect of nicotine 
on dopaminergic neurons. Even though the ultimate goal is to stop or reverse the course 
of neurodegenerative diseases, improvement of symptoms such as cognitive or social 
deficits can have a very positive effect on patients’ quality of life. 
 
Acknowledgements 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
23 
 
This work was supported by the Michael J. Fox Foundation (MJFF), by the Caltech-
UCLA Joint Center for Translational Medicine (JCTM), by NIH grant AG-033954, by gifts 
to the Center for the Study of Parkinson’s disease at UCLA, and by gifts from Louis and 
Janet Fletcher at Caltech. We thank Dr. Franziska Richter and Sheri McKinney for help 
in designing the study. We also thank undergraduate students Bansi Patel, Jacky 
Kwong, Sean Campeau and Diana Dinh for their help with behavior rating and histology. 
MFC has received honoraria (for service as a reviewer) and travel reimbursement from 
MJFF.  
 
Conflict of Interest Statement 
The authors declare that the research was conducted in the absence of any commercial 
or financial relationships that could be construed as a potential conflict of interest. 
 
References 
 
 
Abbott, R. D., et al., 2007. Bowel movement frequency in late-life and incidental Lewy bodies. 
Mov Disord. 22, 1581-6. 
Anderson, R. J., et al., 2013. Social problem solving, social cognition, and mild cognitive 
impairment in Parkinson's disease. Behav Neurosci. 127, 184-92. 
Barker, G. R., Warburton, E. C., 2009. Critical role of the cholinergic system for object-in-place 
associative recognition memory. Learn Mem. 16, 8-11. 
Bassetti, C. L., 2011. Nonmotor disturbances in Parkinson's disease. Neurodegener Dis. 8, 95-
108. 
Bitner, R. S., et al., 2010. In vivo pharmacological characterization of a novel selective α7 
neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in 
Alzheimer's disease. J Pharmacol Exp Ther. 334, 875-86. 
Bloch, A., et al., 2006. α-synuclein pathology of the spinal and peripheral autonomic nervous 
system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 32, 
284-95. 
Boess, F. G., et al., 2013. Pharmacological and behavioral profile of N-[(3R)-1-
azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic 
acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist. Psychopharmacology 
(Berl). 227, 1-17. 
Bohnen, N. I., Albin, R. L., 2009. Cholinergic denervation occurs early in Parkinson disease. 
Neurology. 73, 256-7. 
Bohnen, N. I., et al., 2015. Frequency of cholinergic and caudate nucleus dopaminergic deficits 
across the predemented cognitive spectrum of Parkinson disease and evidence of 
interaction effects. JAMA Neurol. 72, 194-200. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
24 
 
Botton, P. H., et al., 2010. Caffeine prevents disruption of memory consolidation in the 
inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. 
Behav Brain Res. 214, 254-9. 
Braak, H., et al., 2006. Gastric α-synuclein immunoreactive inclusions in Meissner's and 
Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. 
Neurosci Lett. 396, 67-72. 
Braak, H., et al., 2003. Staging of brain pathology related to sporadic Parkinson's disease. 
Neurobiol Aging. 24, 197-211. 
Chaudhuri, K. R., et al., 2011. Parkinson's disease: the non-motor issues. Parkinsonism Relat 
Disord. 17, 717-23. 
Checkoway, H., et al., 2002. Parkinson's disease risks associated with cigarette smoking, alcohol 
consumption, and caffeine intake. Am J Epidemiol. 155, 732-8. 
Chesselet, M. F., Richter, F., 2011. Modelling of Parkinson's disease in mice. Lancet Neurol. 10, 
1108-18. 
Chesselet, M. F., et al., 2012. A progressive mouse model of Parkinson's disease: the Thy1-aSyn 
("Line 61") mice. Neurotherapeutics. 9, 297-314. 
Clemens, P., et al., 1995. The short-term effect of nicotine chewing gum in patients with 
Parkinson's disease. Psychopharmacology (Berl). 117, 253-6. 
Costa, G., et al., 2001. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine 
lesion in the substantia nigra. Brain Res. 888, 336-342. 
de Bruin, N., Pouzet, B., 2006. Beneficial effects of galantamine on performance in the object 
recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the 
retention interval. Pharmacol Biochem Behav. 85, 253-60. 
Edwards, T. L., et al., 2010. Genome-wide association study confirms SNPs in SNCA and the 
MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 74, 97-
109. 
Emre, M., et al., 2004. Rivastigmine for dementia associated with Parkinson's disease. N Engl J 
Med. 351, 2509-18. 
Everitt, B. J., Robbins, T. W., 1997. Central cholinergic systems and cognition. Annu Rev 
Psychol. 48, 649-84. 
Fernagut, P. O., et al., 2007. Behavioral and histopathological consequences of paraquat 
intoxication in mice: effects of α-synuclein over-expression. Synapse. 61, 991-1001. 
Feuerbach, D., et al., 2009. The selective nicotinic acetylcholine receptor α7 agonist JN403 is 
active in animal models of cognition, sensory gating, epilepsy and pain. 
Neuropharmacology. 56, 254-63. 
Fleming, S. M., et al., 2011. A pilot trial of the microtubule-interacting peptide (NAP) in mice 
overexpressing α-synuclein shows improvement in motor function and reduction of α-
synuclein inclusions. Mol Cell Neurosci. 46, 597-606. 
Fleming, S. M., et al., 2004. Early and progressive sensorimotor anomalies in mice 
overexpressing wild-type human α-synuclein. J Neurosci. 24, 9434-40. 
Fleming, S. M., et al., 2008. Olfactory deficits in mice overexpressing human wildtype α-
synuclein. Eur J Neurosci. 28, 247-56. 
Fujita, M., et al., 2006. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's 
disease. Ann Neurol. 59, 174-7. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
25 
 
Gee, K. W., et al., 2017. First in human trial of a type I positive allosteric modulator of α7-
nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for 
neurocognitive effect of AVL-3288. J Psychopharmacol. 269881117691590. 
Gorell, J. M., et al., 1999. Smoking and Parkinson's disease: a dose-response relationship. 
Neurology. 52, 115-9. 
Grace, J., et al., 2009. A double-blind comparison of galantamine hydrobromide ER and placebo 
in Parkinson disease. J Neurol Neurosurg Psychiatry. 80, 18-23. 
Hambsch, B., et al., 2014. Chronic nicotine improves short-term memory selectively in a G72 
mouse model of schizophrenia. Br J Pharmacol. 171, 1758-71. 
Hanagasi, H. A., et al., 2017. Dementia in Parkinson's disease. J Neurol Sci. 374, 26-31. 
Harris, J. G., et al., 2004. Effects of nicotine on cognitive deficits in schizophrenia. 
Neuropsychopharmacology. 29, 1378-85. 
Hatami, A., Chesselet, M. F., 2015. Transgenic rodent models to study α-synuclein pathogenesis, 
with a focus on cognitive deficits. Curr Top Behav Neurosci. 22, 303-30. 
Henderson, B. J., Lester, H. A., 2015. Inside-out neuropharmacology of nicotinic drugs. 
Neuropharmacol. 96, 178-93. 
Henderson, B. J., et al., 2014. Nicotine exploits a COPI-mediated process for chaperone-
mediated up-regulation of its receptors. J Gen Physiol. 143, 51-66. 
Hershey, L. A., Perlmutter, J. S., 2014. Smoking and Parkinson disease: where there is smoke 
there may not be fire. Neurology. 83, 1392-3. 
Hong, D. P., et al., 2009. Smoking and Parkinson's disease: does nicotine affect α-synuclein 
fibrillation? Biochim Biophys Acta. 1794, 282-90. 
Khwaja, M., et al., 2007. Nicotine partially protects against paraquat-induced nigrostriatal 
damage in mice; link to α6β2* nAChRs. J Neurochem. 100, 180-90. 
Kruger, R., et al., 1998. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's 
disease. Nat Genet. 18, 106-8. 
Lam, H. A., et al., 2011. Elevated tonic extracellular dopamine concentration and altered 
dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice 
overexpressing human α-synuclein. J Neurosci Res. 89, 1091-102. 
Lee, K. W., et al., 2011. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a 
mouse model. J Neurosci. 31, 6963-71. 
Lelong-Boulouard, V., et al., 2006. Interactions of buprenorphine and dipotassium clorazepate 
on anxiety and memory functions in the mouse. Drug Alcohol Depend. 85, 103-13. 
Lester, H. A., et al., 2009. Nicotine is a selective pharmacological chaperone of acetylcholine 
receptor number and stoichiometry. Implications for drug discovery. AAPS J. 11, 167-77. 
Magen, I., Chesselet, M. F., 2011. Mouse models of cognitive deficits due to α-synuclein 
pathology. J Parkinsons Dis. 1, 217-27. 
Magen, I., et al., 2012. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. 
Eur J Neurosci. 35, 870-82. 
Magen, I., et al., 2014. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and 
moderately improves behavioral deficits in mice overexpressing α-synuclein. Pharmacol 
Res Perspect. 2, e00065. 
Magen, I., et al., 2015. Social Cognition Impairments in Mice Overexpressing α-Synuclein 
Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease. J Parkinsons 
Dis. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
26 
 
Mamikonyan, E., et al., 2015. Rivastigmine for mild cognitive impairment in Parkinson disease: 
a placebo-controlled study. Mov Disord. 30, 912-8. 
McDowell, K. A., et al., 2014. Sleep dysfunction and EEG alterations in mice overexpressing α-
synuclein. J Parkinsons Dis. 4, 531-9. 
Meyer, P. M., et al., 2009. Reduced α4β2*-nicotinic acetylcholine receptor binding and its 
relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen 
Psychiatry. 66, 866-77. 
Moy, S. S., et al., 2004. Sociability and preference for social novelty in five inbred strains: an 
approach to assess autistic-like behavior in mice. Genes Brain Behav. 3, 287-302. 
Nashmi, R., et al., 2007. Chronic nicotine cell specifically upregulates functional α4* nicotinic 
receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in 
perforant path. J Neurosci. 27, 8202-18. 
Oishi, N., et al., 2007. Quantification of nicotinic acetylcholine receptors in Parkinson's disease 
with (123)I-5IA SPECT. J Neurol Sci. 256, 52-60. 
Ono, K., et al., 2007. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: 
implications for the prevention and therapeutics of Lewy body diseases. Exp Neurol. 205, 
414-24. 
Perry, E. K., et al., 1992. Autoradiographic distribution of [3H]nicotine binding in human cortex: 
relative abundance in subicular complex. J Chem Neuroanat. 5, 399-405. 
Pfeiffer, H. C., et al., 2014. Cognitive impairment in early-stage non-demented Parkinson's 
disease patients. Acta Neurol Scand. 129, 307-18. 
Picciotto, M. R., Zoli, M., 2008. Neuroprotection via nAChRs: the role of nAChRs in 
neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci. 
13, 492-504. 
Pimlott, S. L., et al., 2004. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, 
dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding 
study using 5-[(125)i]-a-85380. Neuropsychopharmacology. 29, 108-16. 
Polymeropoulos, M. H., et al., 1997. Mutation in the α-synuclein gene identified in families with 
Parkinson's disease. Science. 276, 2045-7. 
Poorthuis, R. B., et al., 2009. Nicotinic actions on neuronal networks for cognition: general 
principles and long-term consequences. Biochem Pharmacol. 78, 668-76. 
Postuma, R. B., et al., 2012. Identifying prodromal Parkinson's disease: pre-motor disorders in 
Parkinson's disease. Mov Disord. 27, 617-26. 
Preskorn, S. H., et al., 2014. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, 
on event-related potentials and cognition: a proof of concept, randomized trial in patients 
with schizophrenia. J Psychiatr Pract. 20, 12-24. 
Quik, M., et al., 2015. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease 
and Drug-Induced Movement Disorders. Int Rev Neurobiol. 124, 247-71. 
Quik, M., Jeyarasasingam, G., 2000. Nicotinic receptors and Parkinson's disease. Eur J 
Pharmacol. 393, 223-30. 
Quik, M., et al., 2013. Nicotine reduces established levodopa-induced dyskinesias in a monkey 
model of Parkinson's disease. Mov Disord. 28, 1398-406. 
Quik, M., et al., 2012. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov 
Disord. 27, 947-57. 
Richter, F., et al., 2014a. A GCase chaperone improves motor function in a mouse model of 
synucleinopathy. Neurotherapeutics. 11, 840-56. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
27 
 
Richter, F., et al., 2014b. Chronic administration of cholesterol oximes in mice increases 
transcription of cytoprotective genes and improves transcriptome alterations induced by 
α-synuclein overexpression in nigrostriatal dopaminergic neurons. Neurobiol Dis. 69, 
263-75. 
Rinne, J. O., et al., 1991. A postmortem study of brain nicotinic receptors in Parkinson's and 
Alzheimer's disease. Brain Res. 547, 167-70. 
Ritz, B., et al., 2014. Parkinson disease and smoking revisited: ease of quitting is an early sign of 
the disease. Neurology. 83, 1396-402. 
Rockenstein, E., et al., 2002. Differential neuropathological alterations in transgenic mice 
expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J 
Neurosci Res. 68, 568-78. 
Ross, G. W., et al., 2006. Association of olfactory dysfunction with incidental Lewy bodies. Mov 
Disord. 21, 2062-7. 
Ryan, R. E., et al., 2001. Dose-related neuroprotective effects of chronic nicotine in 6-
hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor 
subunit knockout mice. Br J Pharmacol. 132, 1650-6. 
Salas, R., et al., 2013. Abnormal social behavior in nicotinic acetylcholine receptor β4 subunit-
null mice. Nicotine Tob Res. 15, 983-6. 
Sarter, M., et al., 2009. nAChR agonist-induced cognition enhancement: integration of cognitive 
and neuronal mechanisms. Biochem Pharmacol. 78, 658-67. 
Singleton, A. B., et al., 2003. α-Synuclein locus triplication causes Parkinson's disease. Science. 
302, 841. 
Soleimani, M. A., et al., 2014. Disrupted social connectedness in people with Parkinson's 
disease. Br J Community Nurs. 19, 136-41. 
Sossi, V., et al., 2010. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. 
Mov Disord. 25, 2717-23. 
Spillantini, M. G., Goedert, M., 2000. The α-synucleinopathies: Parkinson's disease, dementia 
with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 920, 16-27. 
Spillantini, M. G., et al., 1997. α-synuclein in Lewy bodies. Nature. 388, 839-40. 
Srinivasan, R., et al., 2014. Pharmacological chaperoning of nAChRs: A therapeutic target for 
Parkinson's disease. Pharmacol Res. 83C, 20-29. 
Srinivasan, R., et al., 2016. Smoking-Relevant Nicotine Concentration Attenuates the Unfolded 
Protein Response in Dopaminergic Neurons. J Neurosci. 36, 65-79. 
Subramaniam, S. R., et al., 2014. Region specific mitochondrial impairment in mice with 
widespread overexpression of α-synuclein. Neurobiol Dis. 70, 204-13. 
Sugita, M., et al., 2001. Meta-analysis for epidemiologic studies on the relationship between 
smoking and Parkinson's disease. J Epidemiol. 11, 87-94. 
Tanner, C. M., et al., 2002. Smoking and Parkinson's disease in twins. Neurology. 58, 581-8. 
Timmermann, D. B., et al., 2012. Augmentation of cognitive function by NS9283, a 
stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic 
acetylcholine receptors. Br J Pharmacol. 167, 164-82. 
Toulorge, D., et al., 2011. Neuroprotection of midbrain dopamine neurons by nicotine is gated by 
cytoplasmic Ca2+. FASEB J. 25, 2563-73. 
Vieregge, A., et al., 2001. Transdermal nicotine in PD: a randomized, double-blind, placebo-
controlled study. Neurology. 57, 1032-5. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
28 
 
Villafane, G., et al., 2007. Chronic high dose transdermal nicotine in Parkinson's disease: an 
open trial. Eur J Neurol. 14, 1313-6. 
Wall, P. M., Messier, C., 2002. Infralimbic κ opioid and muscarinic M1 receptor interactions in 
the concurrent modulation of anxiety and memory. Psychopharmacology (Berl). 160, 
233-44. 
Wallace, T. L., Porter, R. H., 2011. Targeting the nicotinic α7 acetylcholine receptor to enhance 
cognition in disease. Biochem Pharmacol. 82, 891-903. 
Wang, H. F., et al., 2015. Efficacy and safety of cholinesterase inhibitors and memantine in 
cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia 
with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J 
Neurol Neurosurg Psychiatry. 86, 135-43. 
Wang, L., et al., 2012. Mice overexpressing wild-type human α-synuclein display alterations in 
colonic myenteric ganglia and defecation. Neurogastroenterol Motil. 24, e425-36. 
Watson, J. B., et al., 2009. Alterations in corticostriatal synaptic plasticity in mice 
overexpressing human α-synuclein. Neuroscience. 159, 501-13. 
Watson, M. B., et al., 2012. Regionally-specific microglial activation in young mice over-
expressing human wildtype α-synuclein. Exp Neurol. 237, 318-34. 
Wolters, E., 2009. Non-motor extranigral signs and symptoms in Parkinson's disease. 
Parkinsonism Relat Disord. 15 Suppl 3, S6-12. 
Wrasidlo, W., et al., 2016. A de novo compound targeting α-synuclein improves deficits in 
models of Parkinson's disease. Brain. 139, 3217-3236. 
Wu, N., et al., 2010. α-synuclein overexpression in mice alters synaptic communication in the 
corticostriatal pathway. J Neurosci Res. 88, 1764-76. 
Yang, Y., et al., 2016. Parkinson's Disease and Cognitive Impairment. Parkinsons Dis. 2016, 
6734678. 
Zarow, C., et al., 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and 
substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 60, 337-41. 
 
 
Figure Legends 
 
Figure 1. Schematic illustration of the timeline in all experiments. Treatment 
initiation- osmotic mini-pump implantation subcutaneously for one month; Treatment 
maintenance- reimplantation of osmotic mini-pump in the same subcutaneous pocket 
with vehicle or nicotine adjusted for body weight; motor test – challenging beam test and 
vertical pole test; Y-maze test - Y-maze spontaneous alternations test; NOR test- novel 
object recognition test; m – months. 
 
Figure 2. Nicotine treatment improves cognitive defects in Y-maze spontaneous 
alternation test at 7 months of age. One-sample t test on percent alternations 
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compared to chance level of zero was performed. Thy1-aSyn mice treated with vehicle 
showed decreased percentage of alternations at 7 months, but not at 5 months. 
Nicotine treatment at 0.4 mg/kg/h for 5 months (7 months of age) reversed the deficit. 
Data are represented as the mean ± SEM. ♦p<0.05, ∆not significant vs. chance level 
zero compared by one sample t test. A paired t test was also used to compare each 
group at 5 vs 7 months. ^p<0.05 compared to respective group at previous age.  
 
Figure 3. Nicotine treatment improves cognitive defects in novel object 
recognition test in Thy1-aSyn mice at 6 months of age. Thy1-aSyn mice treated with 
vehicle showed decreased discrimination index at 6 months of age. Nicotine treatment 
at 0.4 mg/kg/h for one month abolished this impairment. Data are presented as the 
mean ± SEM. ♦p<0.05 vs. chance level (zero) compared by one-sample t test. 
 
Figure 4. Nicotine treatment for one month improves social impairment in Thy1-
aSyn mice tested at 6 months of age. Thy1-aSyn mice treated with vehicle sniffed a 
beaker with a novel mouse (Mo) for less time than Wt mice treated with vehicle. Vehicle 
treated Thy1-aSyn mice did not show a preference for exploring a novel mouse (Mo) 
over an empty beaker (Em), but nicotine administration at 0.4 mg/kg/h for one month 
restored the interest in a novel mouse. Data are presented as mean ± SEM. Two-way 
repeated measures ANOVA followed by post hoc Bonferroni t test. *p<0.05, Thy1-aSyn-
vehicle compared to Wt-vehicle; ^^p<0.01 compared within the group (empty beaker vs. 
mouse beaker).  
 
Figure 5. Nicotine treatment does not improve motor performance in the 
challenging beam test. Thy1-aSyn mice treated with vehicle showed increased errors 
per step (A) and a progression of the defect from 2 months to 4 months of age (B) 
compared to Wt-vehicle treated mice. Nicotine treatment at both doses did not improve 
this defect initially (A) but partially inhibited the progression of this defect at 4 months of 
age (B). Data are presented as mean ± SEM; Student’s t test or the Mann Whitney U-
test (see Methods) was performed to compare Wt-vehicle vs. Thy1-aSyn-vehicle within 
each time point, ***p<0.001, **p<0.01. One-way ANOVA followed by a Bonferroni t test 
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was performed to compare the effect of treatment in Thy1-aSyn mice. β, Thy1-aSyn-
nicotine-2.0 mg/kg/h group was euthanized before 8 months of age (see Methods). 
 
Figure 6. Nicotine treatment does not improve motor performance in the vertical 
pole test. (A) Thy1-aSyn mice treated with vehicle showed increased total time to turn 
and descend compared to Wt-vehicle treated mice at the ages mentioned. Nicotine 
treatment did not improve this defect. Data are represented as the mean ± SEM; 
Student’s t test or the Mann Whitney U-test (see Methods) was performed to compare 
Wt-vehicle vs. Thy1-aSyn vehicle within each time point, ***p<0.001. One-way ANOVA 
followed by a Bonferroni t test was performed to compare the effect of treatment in 
Thy1-aSyn mice. (B) The percentage of mice performing the pole test was decreased 
by 6 months of age and neared zero in Thy1-aSyn mice. Data are presented as 
percentage performers vs. non-performers. Chi-square test was performed, ***p<0.001 
compared with Wt mice treated with vehicle within the time point tested, ^^p<0.01, 
^^^p<0.001 vs. Wt-vehicle group at pre-treatment, ###p<0.001 vs. Thy1-vehicle group at 
pre-treatment. β = Thy1-aSyn-nicotine-2.0 mg/kg/h group was euthanized before 8 
months of age (see Methods). 
 
Figure 7. Measurement of microglial activation by IBA-1 staining in SN. Thy1-
aSyn-vehicle mice showed no change in Iba-1 staining of activated microglia compared 
to Wt-vehicle mice (A). Nicotine treatment at both doses (0.4 mg/kg/h and 2.0 mg/kg/h) 
did not alter microglial activation compared to Thy1-aSyn-vehicle mice (B, C). Data are 
presented as the mean ± 95% CI. Significance is represented if confidence intervals 
(CI) fall outside 95%, calculated by bootstrapping (*p<0.05). Thy1-aSyn-nicotine-2.0 
mg/kg/h mice were euthanized at 6 months of age (see Methods) and their brains were 
processed for histology.  
 
Table Legends 
 
Table 1. Nicotine treatment did not alter open field hyperactivity in Thy1-aSyn 
mice. Open-field test parameters showed hyperactivity of Thy1-aSyn mice at both 5 and 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
31 
 
8 months of age. Data are presented as the mean ± SEM. Student’s t test or the Mann-
Whitney U-test (if unequal variances exist) was performed to compare Wt-vehicle vs. 
Thy1-aSyn vehicle within each time point, *p<0.05, **p<0.01, ***p<0.001. One-way 
ANOVA followed by a Bonferroni t test was performed to compare the effect of 
treatment in Thy1-aSyn mice. β = Thy1-aSyn-nicotine-2.0 mg/kg/h group was not 
included in the statistical analysis at 8 months of age, because mice in this group were 
euthanized at 6 months of age (see Methods).   
 
Table 2. Nicotine treatment for 6 months did not alter histological parameters in 
SN and striatum. Thy1-aSyn mice showed increased α-synuclein levels overall in SN 
(SNc, SN pars compacta; SNr, SN pars reticulata) compared to Wt mice treated with 
vehicle; and nicotine treatment did not alter these levels. The percentage area occupied 
by the proteinase K-resistant aggregates in SN subregions of Thy1-aSyn mice was not 
altered by nicotine treatment for 6 months. Other parameters show µm
2
 / section. TH 
immunofluorescence was not altered in Thy1-aSyn mice compared to Wt mice treated 
with vehicle in both SN and striatum. Nicotine treatment for 6 months did not change 
nigral or striatal tyrosine TH immunofluorescence compared to vehicle-treated Thy1-
aSyn mice. Thy1-aSyn mice showed no change in striatal synaptophysin or MAP2 
(microtubule-associated protein 2) immunofluorescence compared to vehicle-treated Wt 
mice. Nicotine treatment for 6 months did not alter striatal synaptophysin or MAP2 
immunofluorescence at several levels (rostral, medial and caudal) compared to vehicle-
treated Thy1-aSyn mice. Data are presented as the mean ± SEM; Wt-vehicle (n=8-10), 
Thy1-aSyn-vehicle (n=8-10), Thy1-aSyn-0.4 mg/kg/h (n=8-10), Thy1-aSyn-2.0 mg/kg/h 
(n=8-10); repeated measures ANOVA followed by a post hoc Bonferroni t test. *p<0.05, 
compared to Wt vehicle group within the brain sub-region. ^p<0.05, Thy1-aSyn-0.4 
mg/kg/h group vs Thy1-aSyn-2.0 mg/kg/h group within the brain sub-region. β = Thy1-
aSyn-nicotine-2.0 mg/kg/h mice were euthanized at 6 months of age (see Methods) and 
their brains were processed for histology. 
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Table 1. 
Genotype Wt Thy1-aSyn 
Number of mice tested 
at age 5 months  
at age 8 months  
 
 
34 
32 
 
30 
25 
 
25 
18 
 
18 
β 
 
Nicotine, mg/kg/h 
 
0 0 0.4 2.0 
Move episodes (number) 
5 months 
8 months 
 
Move time (seconds) 
5 months 
8 months 
 
Move time/episode 
(seconds) 
5 months 
8 months  
 
Distance (cm) 
5 months 
8 months 
 
Distance/episode (cm)  
5 months 
8 months 
 
Velocity (cm/second) 
5 months 
8 months 
 
Center entries (number)  
5 months 
8 months 
 
Rears (number) 
5 months 
8 months 
 
 
292 ± 4 
266 ± 5 
 
 
517 ± 14 
442 ± 18 
 
 
1.79 ± 0.06 
1.66 ± 0.07 
 
 
1860 ± 91 
1560 ± 115 
 
 
6.52 ± 0.38 
5.89 ± 0.45 
 
 
3.55 ± 0.11 
3.42 ± 0.11 
 
 
66.8 ± 3.7 
57.0 ± 4.4 
 
 
64.9 ± 5.4 
39.8 ± 5.6 
 
267 ± 6*** 
237 ± 10* 
 
 
595 ± 15*** 
569 ± 30*** 
 
 
2.28 ± 0.10*** 
2.48 ± 0.17*** 
 
 
2540 ± 160** 
2780 ± 270*** 
 
 
9.19 ± 0.76*** 
11.18 ± 
1.06*** 
 
 
4.05 ± 0.15* 
4.71 ± 0.28*** 
 
 
84.2 ± 5.1* 
86.0 ± 8.5** 
 
 
79.7 ± 9.5 
63.8 ± 11.5 
 
252 ± 9 
263 ± 6 
 
 
579 ± 24 
567 ± 23 
 
 
2.29 ± 0.11 
2.12 ± 0.09 
 
 
2550 ± 230 
2630 ± 250 
 
 
10.26 ± 1.03 
8.74 ± 0.56 
 
 
4.41 ± 0.22 
4.51 ± 0.28 
 
 
82.0 ± 7.8 
86.6 ± 5.9 
 
 
77.0 ± 9.9 
55.8 ± 8.6 
 
233 ± 14 
β 
 
 
605 ± 27 
β 
 
 
2.63 ± 0.23 
β 
 
 
2700 ± 340 
β 
 
 
12.49 ± 2.27 
β 
 
 
4.54 ± 0.32 
β 
 
 
87.9 ± 10.5 
β 
 
 
69.2 ± 11.2 
β 
 
 
Table 1. Nicotine treatment did not alter open field hyperactivity in Thy1-aSyn mice. 
Open-field test parameters showed hyperactivity of Thy1-aSyn mice at both 5 and 8 months of 
age. Data are presented as the mean ± SEM. Student’s t test or the Mann-Whitney U-test (if 
unequal variances exist) was performed to compare Wt-vehicle vs. Thy1-aSyn vehicle within 
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each time point, *p<0.05, **p<0.01, ***p<0.001. One-way ANOVA followed by a Bonferroni t test 
was performed to compare the effect of treatment in Thy1-aSyn mice. β = Thy1-aSyn-nicotine-
2.0 mg/kg/h group was not included in the statistical analysis at 8 months of age, because mice 
in this group were euthanized at 6 months of age (see Methods).  
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Table 2. 
Immunohistological 
measurements 
Genotype Nicotine 
mg/kg/h 
Brain Region (with sub-regions) 
 SN 
SNc SNr 
α-synuclein 
(immunofluorescence) 
Wt 
Thy1-
aSyn 
Thy1-
aSyn 
Thy1-
aSyn 
0 
0 
0.4  
2.0 β 
18900 ± 2100 
30100 ± 2400* 
28700 ± 3200* 
26900 ± 2700* 
29900 ± 2400 
35000 ± 2600 
33400 ± 3500 
31500 ± 2400 
α-synuclein 
aggregates  
(proteinase K-
resistant) 
 
Thy1-
aSyn 
Thy1-
aSyn 
Thy1-
aSyn 
 
0 
0.4  
2.0 β 
Dorsolateral Dorsomedial Ventrolateral Ventromedial 
1.16±0.10 
1.14±0.05 
1.21±0.08 
0.99±0.07 
1.03±0.07 
1.06±0.04 
1.11±0.10 
1.18±0.08 
1.35±0.09 
1.18±0.08 
1.17±0.07 
1.20±0.07 
TH 
(immunofluorescence) 
 
 
Wt 
Thy1-
aSyn 
Thy1-
aSyn 
Thy1-
aSyn 
 
0 
0 
0.4  
2.0 β 
SNc SNr 
13400 ± 880 
13500 ± 610 
15300 ±1300  
12700 ± 840^ 
7570 ± 450 
7380 ± 370  
7570 ± 550 
6870 ± 400 
 striatum 
Rostral Medial Caudal 
TH 
(immunofluorescence) 
 
Wt 
Thy1-
aSyn 
Thy1-
0 
0 
0.4  
2.0 β 
23000 ± 1200  
22400 ± 1400 
23800 ± 1100 
20200 ± 1500^ 
19270 ± 1310  
18090 ± 1140 
19740 ± 1360 
17140 ± 890 
19100 ± 930 
17110 ± 930 
19100 ±1100 
16400 ± 490 
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aSyn 
Thy1-
aSyn 
Synaptophysin 
(immunofluorescence) 
Wt 
Thy1-
aSyn 
Thy1-
aSyn 
Thy1-
aSyn 
0 
0 
0.4  
2.0 β 
47200 ± 1700 
47300 ± 2200 
46100 ±1500 
52700 ±1800 
33200 ± 1500 
30700 ± 1700 
31200 ± 1500 
34300 ± 1700  
33400 ± 1900 
29700 ± 1300 
31600 ± 1200 
33200 ± 1600 
MAP2 
(immunofluorescence) 
 
Wt 
Thy1-
aSyn 
Thy1-
aSyn 
Thy1-
aSyn 
0 
0 
0.4  
2.0 β 
33600 ± 1700 
38200 ± 2000 
33300 ± 2100 
34800 ± 2200 
29500 ± 2500 
30200 ± 2100 
27900 ± 1000 
30700 ± 2500 
30100 ± 2700 
30600 ± 1700 
28900 ± 1000 
30600 ± 2000 
Table 2. Nicotine treatment for 6 months did not alter histological parameters in SN and striatum. Thy1-aSyn mice 
showed increased α-synuclein levels overall in SN (SNc, SN pars compacta; SNr, SN pars reticulata) compared to Wt 
mice treated with vehicle; and nicotine treatment did not alter these levels. The percentage area occupied by the 
proteinase K-resistant aggregates in SN subregions of Thy1-aSyn mice was not altered by nicotine treatment for 6 
months. Other parameters show µm2 / section. TH immunofluorescence was not altered in Thy1-aSyn mice compared to 
Wt mice treated with vehicle in both SN and striatum. Nicotine treatment for 6 months did not change nigral or striatal 
tyrosine TH immunofluorescence compared to vehicle-treated Thy1-aSyn mice. Thy1-aSyn mice showed no change in 
striatal synaptophysin or MAP2 (microtubule-associated protein 2) immunofluorescence compared to vehicle-treated Wt 
mice. Nicotine treatment for 6 months did not alter striatal synaptophysin or MAP2 immunofluorescence at several levels 
(rostral, medial and caudal) compared to vehicle-treated Thy1-aSyn mice. Data are presented as the mean ± SEM; Wt-
vehicle (n=8-10), Thy1-aSyn-vehicle (n=8-10), Thy1-aSyn-0.4 mg/kg/h (n=8-10), Thy1-aSyn-2.0 mg/kg/h (n=8-10); 
repeated measures ANOVA followed by a post hoc Bonferroni t test. *p<0.05, compared to Wt vehicle group within the 
brain sub-region. ^p<0.05, Thy1-aSyn-0.4 mg/kg/h group vs Thy1-aSyn-2.0 mg/kg/h group within the brain sub-region. β = 
Thy1-aSyn-nicotine-2.0 mg/kg/h mice were euthanized at 6 months of age (see Methods) and their brains were processed 
for histology.  
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